Skip to main content
SpringerLink
Log in

Tecovirimat: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Tecovirimat (TPOXX®) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services’ Biomedical Advances Research and Development Authority. It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host. In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg. Tecovirimat was approved under the US FDA’s Animal Rule, in which marketing approval is based on its efficacy in relevant animal models. An intravenous formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection. This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US FDA. FDA approves the first drug with an indication for treatment of smallpox; 2018. http://www.fda.gov/. Accessed 16 July 2018.

  2. Grosenbach DW, Jordan R, Hruby DE. Development of the small-molecule antiviral ST-246R as a smallpox therapeutic. Future Virol. 2011;6(5):653–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Jordan R, Leeds JM, Tyavanagimatt S, et al. Development of ST-246R for treatment of poxvirus infections. Viruses. 2010;2(11):2409–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. SIGA Technologies Inc. TPOXX (tecovirimat) capsules for oral use: US prescribing information; 2018. http://www.fda.gov/. Accessed 26 July 2018.

  5. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. SIGA Technologies Inc. U.S. Food and Drug Administration approves SIGA Technologies’ TPOXX® (tecovirimat) for the treatment of smallpox [media release]. 13 July 2018. http://www.siga.com/.

  7. Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005;79(20):13139–49.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Leeds JM, Fenneteau F, Gosselin NH, et al. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother. 2013;57(3):1136–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012;56(9):4900–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Jordan R, Tien D, Bolken TC, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008;52(5):1721–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother. 2012;56(7):3582–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother. 2010;54(6):2560–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Tecovirimat: First Global Approval. Drugs 78, 1377–1382 (2018). https://doi.org/10.1007/s40265-018-0967-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-0967-6

Search

Navigation